Drug intelligence / Profile preview

PYC36

Development stage: Unknown
Lead developer: Phylogica
Modality: Cyclic Peptides → Modified Peptides → Peptides
Administration: Oral, Parenteral

Overview

**PYC36** is a synthetic Phylomer peptide developed as an anti-inflammatory therapeutic candidate. Phylomers are proprietary bicyclic peptides derived from bacterial proteomes, designed for high stability and target specificity. PYC36 targets the **AP-1 pathway**, a key transcription factor complex mediating inflammatory responses through proteins like c-Fos and c-Jun. It was part of a family of anti-inflammatory Phylomers (including PYC35, PYC38, PYC98) advanced by Phylogica Ltd. in collaboration with Bio-Link Partners Ltd. for commercialization, though no recent clinical data or development updates are available, suggesting early preclinical or discovery stage.[3]

Other names: PYC-36PYC36PYC 36

Targets

JUN (Transcription factor Jun)

Beyond the preview

Go deeper on PYC36.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYC36.

Explore the full profile